Polo-like kinase 4 shapes up.

Michelle S Levine, Andrew J Holland

Abstract readComment

In one paragraph

Article in Structure (London, England : 1993), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

Polo-like kinase 4: A molecular linchpin in cancer and its management.iScience · 2025
Review
Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer Management.Molecular cancer therapeutics · 2021
Review
Master regulator genes and their impact on major diseases.PeerJ · 2020
Article
Building a ninefold symmetrical barrel: structural dissections of centriole assembly.Open biology · 2015
Review
PLK4 is a potential therapeutic target in nonmelanoma skin cancers: Evidence from molecular and in vivo studies.Photochemistry and photobiology
Article

4 · The record

Corrections and comments

Comment on
Structure of the C. elegans ZYG-1 cryptic polo box suggests a conserved mechanism for centriolar docking of Plk4 kinases.2014

5 · Who and what money

Authors and funding

2 authors.

Michelle S LevineDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Andrew J HollandDepartment of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: aholland@jhmi.edu.

Funding

Centrosome biogenesis and copy number controlR01GM114119 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI CORMACK, BRENDAN · 2015 to 2023

$3.3M

The role of centrosome amplification in cell growth and tumorigenesisF31GM122288 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI LEVINE, MICHELLE · 2017 to 2018

$74k

Austrian Science Fund FWF P 23440NIGMS NIH HHS F31 GM122288NIGMS NIH HHS R01 GM114119

6 · The paper itself

Abstract

Polo-like kinase 4 (Plk4) is a master regulator of centriole duplication and targets to centrioles through the association of its cryptic polo box domain with centriole receptors. In this issue of Structure, Shimanovskaya and colleagues unveil a new dimeric architecture of Plk4's cryptic polo box that reveals a conserved mechanism for centriole targeting of the kinase.

Indexed as

Models, MolecularAnimalsCaenorhabditis elegansCaenorhabditis elegans ProteinsCentriolesProtein KinasesProtein Serine-Threonine KinasesCaenorhabditis elegans ProteinsProtein KinasesProtein Serine-Threonine Kinaseszyg-1 protein, C elegans

Identifiers

PMID25099950

DOI10.1016/j.str.2014.07.004

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.